Aptevo Therapeutics Reports Third Quarter 2026 Financial Results

Aptevo Therapeutics (APVO) has released its financial results for the third quarter of 2026. The company reported a net loss of $6.5 million for the quarter, which represents an improvement compared to the $7.5 million net loss recorded during the same period in 2025. As of September 30, 2026, Aptevo's cash and cash equivalents stood at $8.3 million, a decrease from the $9.8 million reported at the end of the second quarter. The company also noted recent activity regarding the exercise of existing warrants, which generated $3 million in gross proceeds.

By https://seekingalpha.com/user/52365730/bio · Seeking Alpha ·

Aptevo Therapeutics Reports Third Quarter 2026 Financial Results

Tickers: $APVO

Topics: cash position net loss warrant exercise

Read the full article at Seeking Alpha

Part of the story Elah Holdings, Inc. Releases Third Quarter 2026 Financial Statements (8 articles)

More World news